

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)


PCT

(10) International Publication Number  
WO 2004/037371 A2

- (51) International Patent Classification<sup>7</sup>: **B01D**
- (21) International Application Number:  
PCT/US2003/033354
- (22) International Filing Date: 21 October 2003 (21.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/420,065 21 October 2002 (21.10.2002) US
- (71) Applicant (*for all designated States except US*):  
JANSSEN PHARMACEUTICAL N.V. [BE/BE];  
Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): BARBIER, Ann, Johanna [BE/US]; 7421 Eads Avenue, La Jolla, CA 92037 (US). WILSON, Sandy, J. [US/US]; 10669 Carmel Mountain Road, San Diego, CA 92129 (US). MAZUR, Curt [US/US]; 943 Armada Terrace, San Diego, CA 92106 (US).
- (74) Agents: ELDERKIN, Dianne et al.; Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE

### FAAH Assay



(57) Abstract: The invention provides methods of assaying fatty acid amide hydrolase (FAAH) activity adaptable for high throughput screening. The methods provide for separating a labeled substrate from at least one labeled hydrolysis product, the separation facilitating the quantification. The invention also provides methods of identifying a compound to be tested as an inhibitor or an activator of FAAH activity through the addition of the compound to be tested to a reaction mixture and comparison of the enzyme activity in the presence and absence of the compounds to be tested. The methods are adaptable for use in detecting altered FAAH activity in patients, for example, those at risk for *in vitro* fertilization failure, or at risk for, or suffering, addictions.

## Assay for Determining the Activity of Fatty Acid Amide Hydrolase

### Field of the Invention

The present invention relates to methods for determining the activity of and  
5 identifying modulators of fatty acid amide hydrolases. More specifically, the  
invention relates to an assay, adaptable for high throughput screening, for compounds  
that alter fatty acid amide hydrolase activity.

### Background

10 The identification of anandamide (N-arachidonylethanolamine, AEA) as an  
endogenous ligand for the cannabinoid 1 receptor (Devane *et al.* (1992) *Science*  
258:1946-1949) evoked much scientific interest in the function of bioactive lipids.  
Other examples of endogenous ligands are oleamide (*cis*-9,10-octadecenoamide), best  
known for its sleep-inducing properties (Cravatt *et al.* (1995) *Science* 268:1506-  
15 1509), and 2-arachidonoylglycerol, reported to be neuroprotective after brain injury  
(Panikashvili *et al.* (2001) *Nature* 413:527-531).

The main mechanism for the termination of the biological activity of  
anandamide is hydrolysis (Giuffrida *et al.* (2001) *J. Pharmacol. Expt. Ther.* 298:7-  
14); the existence of an anandamide transporter has also been proposed (Compton and  
20 Martin (1997) *J. Pharmacol. Expt. Ther.* 263:1138-1143).

The enzyme responsible for the hydrolysis of anandamide, oleamide and 2-  
arachidonoylglycerol was cloned in 1996 and named fatty acid amide hydrolase, or  
FAAH (Cravatt *et al.* (1996) *Nature* 384:87-87). FAAH (EC 3.5.1.4) is a membrane-  
bound enzyme with broad substrate specificity which is expressed in a wide variety of

human tissues and cell lines (for review see Ueda *et al.*, *Chem.Phys.Lipids.* 108: 107-121, (2000); Fowler *et al.*, *Biochem. Pharmacol.* 62: 517-526, (2001)).

Inhibitors of FAAH have been predicted to potentiate the effects of the endogenous cannabinoids and thereby promote sleep, muscle relaxation and analgesia (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526). Efforts to identify useful inhibitors have been hampered by the lack of simple, reproducible assays suitable for high-throughput screening. Published methods include reversed phase HPLC (9) and thin-layer chromatography (Deutsch and Chin (1993) *Biochem. Pharmacol.* 46:791-796). A fluorescence displacement method has also been described (Thumser *et al.* (1997) *Biochem. Pharmacol.* 53:433-437). An additional assay relies on extraction of the hydrolysis product with a chloroform: methanol mixture (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86), followed by counting of radioactivity. However, the toxicity of the chloroform and the cumbersome physical manipulations of this method preclude the adaptation of this assay to a high-throughput format.

There is a need in the art, therefore, for improved FAAH assays, particularly those which can be adapted to high throughput screening, for determining the activity of FAAH and for identifying modulators of FAAH.

## SUMMARY OF THE INVENTION

In one aspect, the instant invention provides methods for assaying the activity and amount of fatty acid amide hydrolase (FAAH) based on differences in the physicochemical and binding properties of a FAAH substrate, and the products of its hydrolysis. For example, anandamide is hydrolyzed by FAAH to arachidonic acid and ethanolamine (Fig. 1). In brief, a substrate, for example  $^3\text{H}$ -anandamide (ethanolamine 1- $^3\text{H}$ ), is incubated with a putative source of FAAH activity in a

reaction mixture. The FAAH activity, where present, catalyzes the hydrolysis of the substrate to form at least one radiolabeled hydrolysis product; the example substrate <sup>3</sup>H-anandamide is converted to labeled ethanolamine and unlabeled arachidonic acid. This labeled product and the labeled substrate are separated from each other and the  
5 loss of labeled substrate, or preferably, the formation of labeled product, is measured. In certain preferred embodiments, the assays are performed in parallel or in sets wherein assays conducted in the presence of compounds to be tested for their ability to modulate the FAAH activity are compared with those conducted in the absence of the compounds to be tested. In other preferred embodiments samples from patients  
10 can be assayed to determine if the FAAH activity is altered relative to a predetermined activity value.

In one aspect, the invention provides improved methods of measuring fatty acid amide hydrolase activity comprising combining a sample suspected of containing fatty acid amide hydrolase, with a labeled substrate of fatty acid amide hydrolase to  
15 form a reaction mixture; incubating the reaction mixture under conditions which allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material wherein the selective binding material binds either the labeled substrate or the labeled product, but not both, thereby forming a  
20 bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining the amount of labeled substrate hydrolyzed or the amount of labeled hydrolysis product formed; thereby indicating the fatty acid amide hydrolase activity of the sample.

In another aspect of the invention, methods are provided for identifying compounds which can modulate the activity of a FAAH enzyme. The methods comprise the steps of comparing the activity of a FAAH as assayed by the above method in the presence and in the absence of a test compound added to the reaction  
5 mixture; wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase. In various embodiments, the methods can be used to identify useful inhibitors or enhancers of FAAH activity.

The assay methods provided herein are adaptable for use in high throughput  
10 screening systems and are contemplated to be used in drug discovery efforts. High throughput screening using the assay methods of the present invention will allow libraries of test compounds (for example, libraries produced by techniques of combinatorial chemistry) to be used in rational screening programs to identify inhibitors and enhancers of FAAH activity which are useful as candidates for drugs

15 In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow  
20 a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled  
25 complex from the unbound labeled compound, thereby effectuating a separation of the

labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has  
5 altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

These and other aspects of the present invention will be described in further detail in the Detailed Description set forth below.

## 10 BRIEF DESCRIPTION OF THE FIGURES

**Figure 1:** Schematic diagram of a FAAH assay. The FAAH activity in T84 membranes converts anandamide [1-  $^3\text{H}$ -ethanolamine] into radiolabeled ethanolamine and unlabeled arachidonic acid. The labeled anandamide and unlabeled arachidonic acid are selectively bound to charcoal in filterplates, whereas the  
15 radiolabeled ethanolamine is collected in the flow-through and counted.

**Figure 2** depicts an embodiment of a FAAH assay method. The reaction takes place in a reaction plate at room temperature. After 60 minutes, 60  $\mu\text{l}$  of the reaction mixture is transferred to a charcoal-filled filter plate. The filter plate is fitted on top of a Dynex plate; the assembly is then centrifuged for 5 minutes at 2000 rpm.

20 **Figure 3:** Arachidonic acid and anandamide, but not ethanolamine, bind to activated charcoal. Four different radiolabeled tracers were used: anandamide [1-  $^3\text{H}$ -ethanolamine], anandamide [arachidonyl-5,6,8,9,11,12,14,15- $^3\text{H}$ ], arachidonic acid [5,6,8,9,11,12,14,15- $^3\text{H}$  (N)] and ethanolamine ([2- $^{14}\text{C}$ ] ethan-1-ol-2-amine hydrochloride). The tracers were incubated with membranes prepared from mouse  
25 liver, T84 cells, HeLa cells or with vehicle, for 60 minutes at room temperature. The

percentage (calculated from the average of triplicate determinations  $\pm$  Standard Error of the mean (s.e.m.)) of total radioactivity recovered in the flow-through is shown.

**Figures 4A-4B:** Characterization of a preferred assay. **A:** Time-course of hydrolysis of  $^3\text{H}$ -anandamide by FAAH at room temperature and at  $37^\circ\text{C}$ . The average of triplicate determinations  $\pm$  s.e.m. is shown. **B:** Determination of  $K_m$  for FAAH. T84 cell membranes (3.5  $\mu\text{g}$  protein per well) were incubated with a range of concentrations of  $^3\text{H}$ -anandamide. The reactions were carried out at room temperature in the presence or absence of inhibitors (either oleyl trimethylfluoro ketone (OTFMK) or methyl arachidonyl fluorophosphate (MAFP)). The experiment where oleyl trimethylfluoro ketone was used to determine nonspecific binding is shown; the results with MAFP were comparable. Each point reflects the average of triplicate determinations  $\pm$  s.e.m.

#### DETAILED DESCRIPTION OF THE INVENTION

The reference works, patents, patent applications, and scientific literature, including sequences denoted by their accession numbers (e.g. accession numbers to GenBank database sequences), that are referred to herein are hereby incorporated by reference in their entireties.

Various definitions are used throughout this document. Most words have the meaning that would be attributed to those words by one skilled in the art. Words specifically defined either below or elsewhere in this document have the meaning provided in the context of the present invention as a whole, and as are typically understood by those skilled in the art. Where possible undefined words should be understood to have the usual meaning to the skilled artisan. Any conflict however between an art-understood definition of a word or phrase and a definition of the word

or phrase as specifically taught in this specification shall be resolved in favor of the latter.

Standard reference works setting forth the general principles of recombinant DNA technology known to those of skill in the art include Ausubel *et al.*, Current  
5 Protocols in Molecular Biology, John Wiley & Sons, New York (2002); Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Plainview, New York (2001); Kaufman *et al.*, Eds., Handbook of Molecular and Cellular Methods in Biology and Medicine, CRC Press, Boca Raton (1995).

As used herein, a "label" is a composition detectable by spectroscopic,  
10 photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes and fluorescent labels. Examples of radioisotopes that may be used in the method of the invention include  $^3\text{H}$  and  $^{14}\text{C}$ .

As used herein, "purified" refers to at least partial separation of a molecule from other molecules with which it is normally associated. For example, a purified  
15 protein is a protein that is at least partially separated from other cellular material with which it is normally associated.

As used herein, the term "murine" means originating in a member of the family *Muridae*. A murine FAAH preferably originates in a mouse, or rat.

In a first aspect the invention provides methods of assaying a fatty acid amide  
20 hydrolase (FAAH). In a presently preferred embodiment, the method of assay comprises the steps of combining a sample suspected of containing a FAAH with a labeled substrate of FAAH to form a reaction; incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, forming one or more labeled hydrolysis products; contacting the incubated  
25 reaction mixture with a selective binding material; wherein the selective binding



material binds either the labeled substrate or a labeled hydrolysis product, but not both, to form a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.

The sample, in preferred embodiments, is a biological sample, or a sample comprising biological material, in particular biological membranes. In other preferred embodiments, the sample is from a purification step in the purification of FAAH from a biological source. The sample comprises biological membranes or portions thereof, or comprises lipid bilayers, or artificial membrane systems, monolayers, vesicles or micelles. A sample in some embodiments comprises a purified or recombinant FAAH reconstituted into a phospholipid-containing reaction mixture.

The substrate may be any substrate, putative substrate, or substrate analog of FAAH. The assay is also adapted for use to determine the utility of a compound as a substrate of FAAH. Substrates preferred for use in various embodiments of the present invention include, but are not limited to endocannabinoids or analogs thereof, fatty acid ethanolamides or analogs thereof, fatty acid primary amides or analogs thereof, and analogs of any of the foregoing labeled with a detectable label. Presently preferred substrates of particular interest include, for example, anandamide, oleamide, and 2-arachidonoylglycerol.

The substrate may be radioisotopically labeled in any manner known in the art for labeling compounds for detection. Presently preferred isotopes, such as  $^3\text{H}$  or  $^{14}\text{C}$ , are readily detected via liquid scintillation counting and can facilitate adaptation of

the assays for high throughput drug screening. Synthetic substrates so labeled are readily available commercially or can be synthesized.

Other labels such as fluorescent labels capable of detection, for example fluorimetric detection, are also readily adapted to high throughput screening.

- 5 Preferred fluorescent labels are detectable in biological systems with both proteins and nucleic acids present, therefore preferred labels when assaying cruder cell lysates and homogenates possess both excitation and emission optima which are not masked by these other biological components. In one embodiment the unhydrolyzed labeled substrate has identical fluorescent properties with the hydrolysis product. It is also  
10 possible to design substrates wherein hydrolysis results in a change in fluorescence, for example, where a dye-dye interaction in the unhydrolyzed molecule is required to maintain a ground state. Such substrates are useful in conjunction with the present invention. Colorimetric labels are also contemplated for use herein. Generally, appropriate labels are those which do not alter the substrate's susceptibility to  
15 hydrolysis by the enzyme and for which detection systems have been developed.

- Preferably the substrate is present at concentrations at vast excess relative to the concentration of the enzyme. Under such conditions classical enzyme kinetics can be used to determine a rate constant ( $K_m$ ) and a velocity ( $V_{max}$ ) of the reaction. Kinetic studies are useful for mechanistic studies; they are also powerful tools for  
20 evaluating inhibitors (see below). Standard texts directed at those skilled in the art of enzyme kinetics such as Segel, I.H., *Enzyme Kinetics : Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems* (1993, Wiley-Interscience, ISBN 0471303097) provide complete guidance to establishing these parameters and demonstrate the use, for example, of Lineweaver-Burke plots as graphical tools to  
25 simplify the determination of the kinetic parameters.

High throughput screening systems are known in the art. Such systems often involve the use of multiwell plates to increase the number of assays conducted simultaneously from a few to a hundred, a few hundred or even a few thousand. Presently preferred high throughput screening adaptations of the methods of the present invention provide capability of screening about one hundred to about one or more thousand assays in a short time. Presently preferred high throughput screening systems include robotic components for example for sample handling, dispensing, reagent addition, and other functions to improve accuracy and eliminate the labor intensive aspects of large numbers of assays. Detection systems for high throughput screening programs are known to those of ordinary skill in the art. Preferred detection systems include, but are not limited to, scintillation counting (including, for example, solid and liquid scintillation for counting gamma or beta particles, or luminescent samples, filter counting, Cerenkov counting, and scintillating microplate counting), fluorescence detection (including, for example, intensity, fluorescence polarization, time-resolved fluorescence, fluorescence resonance energy transfer (FRET)), luminescence, and absorbance.

In a presently preferred embodiment, to achieve high-throughput screening, samples are placed on a multicontainer carrier or platform. A multicontainer carrier facilitates measuring reactions of a plurality of candidate compounds simultaneously. For illustration purposes, but not by way of limitation, a multi-well microplate, such as a 96 or a 384 well microplate, that can accommodate 96 or 384 different test reactions, is used as the carrier. Such multi-well microplates, and methods for their use in numerous assays, are both known in the art and commercially available through sources such as Sigma Chemical Co., BIOCHEMICAL ORGANIC COMPOUND AND DIAGNOSTIC REAGENTS, 2002, pages 2495-2511.

The methods of the present invention are adaptable to miniaturization techniques. Assays for purposes of high throughput screening are often conducted in small volumes. Procedures are currently known to those of skill in the art of reducing volumes of assays in a variety of ways. Microfluidics and microcapillary  
5 methodologies now enable assays to be performed down to nanoliter quantities. It is to be understood that the basic principles of the methods and assays apply notwithstanding the volume of the assay, or the manner in which the materials are measured or transported.

The process of determining incubation conditions is routine in the art.  
10 Preferred incubation conditions relate, for example, to enzyme stability. Temperature optimums are routine to determine given the specification of the assay and should be determined for a given enzyme and substrate combination for optimum results. Times and other conditions for incubation involve likewise routine determinations. Preference is given to those conditions which result in linearity of the assay.  
15 Presently preferred temperatures and times include room temperature for 1 hour, or 37 °C for 30 min, using FAAH from a variety of sources and using anadamide as a substrate. Standard texts directed at those skilled in the art of enzyme assays such as Segel, *supra*, provide complete guidance to optimizing assays, including the incubation conditions. Further characterization of the preferred embodiments is  
20 provided in the working examples.

The methods also comprise a step wherein the incubated reaction mixture is contacted with a selective binding material. It is important to note that the selective binding material preferred for this assay may vary with the substrate selected. The selective binding materials comprise materials which can readily be separated from  
25 the bulk reaction mixture by separation techniques which are known in the art.

Effective separations can be based on differences in particle size, density, composition and magnetic susceptibility. Material is separated from a reaction mixture by, for example, gravity settling, filtration (including, for example, membrane separations), centrifugation, A presently preferred method of contacting the incubated  
5 reaction mixture with a selective binding material comprises activated charcoal.

Where the substrate is anandamide, for example, activated charcoal binds, through adsorption, the substrate and one of the hydrolysis products, arachidonic acid. The other hydrolysis product, ethanolamine, does not adsorb to the activated charcoal. For preferred embodiments, the anandamide substrate is labeled on the ethanolamine  
10 moiety. The FAAH hydrolyzes the labeled anandamide into labeled ethanolamine and unlabeled arachidonic acid. After adsorption of the labeled substrate and the unlabeled arachidonic acid to the charcoal, the labeled ethanolamine in solution can be separated from the bound labeled substrate through a simple filtration step. This facilitates the measurement of product without interference from substrate. By  
15 removing some compounds through the binding process, the sample is less likely to interfere, for example by quenching, with the measurement of the labeled product. Existing technology has already been adapted for filtering large numbers of samples simultaneously, for example in multiwell filters. This attribute also is adaptable therefore to high throughput screening programs.

20 Although it is often preferred to measure the formation of product in the methods of this invention, assay conditions and selective binding material may be selected wherein the disappearance of substrate is measured. This indirect method is adaptable particularly where a partially purified or substantially purified enzyme is used, or where it is known that there is only one route by which substrate disappears  
25 from the reaction mixture. It is also preferred to measure substrate disappearance

wherein a selective binding material which binds the substrate is not readily available.

This can be useful in particular in embodiments where the substrate cannot practicably be bound to effect its separation from free hydrolysis product but where the hydrolysis product can be more readily bound to effectively separate it from the free labeled substrate. This gives a practitioner the flexibility to choose from a broader range of selective binding materials.

The determination of the amount of labeled substrate hydrolyzed or the labeled hydrolysis product formed is preferably a direct method of quantitating the amount of label present. As discussed above, a variety of detection techniques are suitable for the present invention, and an appropriate detection method relates to the properties of the label present on the substrate or the product. Presently preferred for use with the methods of the invention are radioisotopically labeled substrates and fluorescently labeled substrates, quantified respectively by scintillation counting and fluorescence detection, respectively. In one preferred embodiment, the substrate is  $^3\text{H}$ - anandamide, the detection is of the product,  $^3\text{H}$ -ethanolamine, formed, and the detection is with a liquid scintillation counting plate reader from the filtrate of an assay conducted in a multiwell plate.

In another aspect of the invention, methods are provided for identifying modulators of fatty acid amide hydrolase. The methods comprise comparing the activity of fatty acid amide hydrolase as assayed by the method as described herein above, in the presence and in the absence of a test compound added to the reaction mixture; a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.

In preferred embodiments, the modulator to be identified is part of compound library, for example, a library of compounds formed by combinatorial chemistry, or a

library of related compounds identified or synthesized as part of a research program.

The putative modulators (i.e. the compounds to be tested, test compounds) are preferably a small molecule with properties that would allow it to have utility for pharmaceutical compositions. Preferred modulators have low nonspecific toxicity,  
5 and high specificity for modulating FAAH.

Modulators include inhibitors of FAAH activity and activators of FAAH.

Assay parameters such as concentration of substrate, incubation conditions, and concentration of compounds to be tested may be varied to more fully appreciate the modulation effects of a test compound.

10 Preferred modulators that are inhibitors can be identified by their ability to decrease the activity of FAAH relative to that of a control reaction mixture lacking the test compound. Preferably, reaction volumes are maintained constant by adjusting the volume to compensate for the addition of a test compound where the addition of a test compound alters the reaction volume. Most preferably any difference in volume is  
15 compensated for by a corresponding addition of a volume, equal to the difference, of the vehicle in which the test compounds are dissolved.

In one aspect of the invention, the modulator identified is an inhibitor of the FAAH activity. Enzyme inhibitors include reversible and irreversible inhibitors.

Preferred inhibitors in some embodiments are reversible inhibitors. Reversible  
20 inhibitors of FAAH include competitive inhibitors, which raise the apparent  $K_m$  of the reaction, noncompetitive inhibitors, which reduce the  $V_{max}$  of the enzyme, and inhibitors which affect both  $K_m$  and  $V_{max}$ , namely, mixed inhibitors and uncompetitive inhibitors. The type of inhibitor identified in screens can be determined through the use of kinetic assay studies according to the methods of the present invention. For the  
25 purposes of the present invention, however, any compound which decreases the

apparent activity of the enzyme is considered a modulator of the inhibitor type. In other preferred embodiments inhibiting modulators include irreversible inhibitors as well as noncompetitive inhibitors, whose action may be irreversible.

In preferred embodiments the test compound inhibits the FAAH reproducibly, as determined by a statistically significant difference by an appropriate statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, the test compound inhibits fatty acid amide hydrolase activity about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 10 or 90%, or about 95% or more, or up to 100%. In other preferred embodiments, the inhibitor statistically significantly increases the apparent  $K_m$  or decreases the  $V_{max}$  of the reaction.

In another aspect of the invention, the test compound increases fatty acid amide hydrolase activity. Various types of enzyme activators are known to those of skill in the art. Some activators are known to activate enzyme reactions by increasing the velocity of the reaction, others are known to alter the equilibrium attained. Activators that combine reversibly with enzyme reaction components (for example, the enzyme, the substrate, or enzyme-substrate or enzyme-product intermediates) to increase the velocity of the reaction are presently preferred. Nonspecific activators may also increase the reaction rate. For purposes of the present invention, any compound that increases the apparent activity of the enzyme is considered a modulator of the activator type. For example many enzymes are known to have increased activity in the presence of certain anions. Other enzymes, in particular those acting on water-insoluble and charge-neutral molecules, are activated by



negatively charged lipophilic molecules. Some membrane bound enzymes are known to be activated, for example, by specific phospholipids.

In preferred embodiments the test compound activates the FAAH reproducibly, as determined by a statistically significant difference by an appropriate statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, fatty acid amide hydrolase activity is increased about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or about 95% or more, or up to 100%. In other embodiments, activation is 10-30%, 30-50%, 50-70%, 70-90%, 90-110%. In some embodiments, the activator increases FAAH activity 100-300%, 300-500%, 500-700%, or 700-900% or more.

In certain preferred embodiments of the methods of the invention, the fatty acid amide hydrolase is a crude cell lysate or a cell homogenate. In some embodiments the FAAH is isolated partially or substantially from cells. In other embodiments, the fatty acid amide hydrolase is recombinantly produced. The fatty acid amide hydrolase may be from any biological source including mammalian fatty acid amide hydrolases from such animals as pigs, rodents (including rats and mice), and humans, or it may be recombinant FAAH produced in any organism known to be useful for the production of recombinant proteins. Synthetic FAAH based on a particular known amino acid sequence, or on a consensus or combination of any number of sequences that result in an active FAAH is also contemplated for use herein.

Examples of known amino acid sequences of fatty acid amide hydrolases from various biological sources include, for example, SEQ ID NOS: 2, 4, 6, and 8.

Examples of known nucleic acid sequences encoding fatty acid amide hydrolases

include SEQ ID NOS:1, 3, 5 and 7. Persons of ordinary skill in the art will recognize that such sequences and the modifications thereof which retain activity, can be used in accordance with the techniques found in references such as those provided above to generate, for example, biological FAAH, recombinant FAAH, overproduced FAAH, or genetically modified FAAH. It is contemplated herein that any form of FAAH is adapted for assay with the methods of the present invention.

In a preferred embodiment the assay is used to measure the activity and identify modulators of FAAH with altered amino acid sequences. Such altered FAAH can result from mutations in the genes which encode FAAH enzymes. In one embodiment, the assay is used to study the activity of, and identify modulators of, altered FAAH in connection with cannabis abuse. For example, a recent paper by Sipe *et al.* (PNAS 99:8394-8398, 2002) describes a strong association between the substitution of Thr for Pro at position 129, and substance abuse in humans. The use of the assay of the present invention may help identify FAAH from humans with higher specific activities or higher levels of net activity, thereby resulting in reduced concentrations of endocannabinoids in the brain, thereby leading to a tendency to seek external cannabinoids to compensate.

In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material; wherein the selective

binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

10            Preferably, the fatty acid amide hydrolase activity from a sample of fluid or tissue originating from the patient is measured. Presently preferred are blood, lymph or tissue samples. In particularly preferred embodiments, the sample is from lymphocytes from the patient. In preferred embodiments, where the sample is from a woman, the results enable a physician to screen pregnant women for risk of

15            miscarriage (spontaneous abortion) or to screen women seeking fertility treatment for risk of failure of *in vitro* fertilization procedures. In preferred embodiments, results from the patient's sample are compared to results from samples of normal individuals, particularly those comparably positioned in terms of demographic criteria. Results of the assays of the present method may be used to determine either or both of altered

20            specific activity (FAAH activity per unit of FAAH mass) or altered total FAAH activity (net amount of product formed per time). For example, increases in activity can be due to increases in specific activity of the FAAH, for example by alteration of the active site via amino acid alteration, gene mutation and the like, or through alteration of the total amount of FAAH protein present, without a change in the

25            specific activity.

In the methods of the invention, the fatty acid amide hydrolase may be substantially purified from the lymphocyte cell lysate. FAAH may be derived from any source, such that the FAAH retains the potential for FAAH activity. For example, FAAH may be purified from cells expressing FAAH, FAAH may be  
5 produced in a recombinant system, including, but not limited to bacterial cells, yeast cells, insect cells, and mammalian cells. FAAH may be derived from any organism that produces FAAH. For example, FAAH may be derived from mammalian cells such as human cells, rodent cells (*e.g.*, mouse and rat cells), or from any other organism that produces FAAH that has FAAH activity. Recombinant FAAH may be  
10 produced using techniques known in the art with any nucleic acid sequence encoding FAAH. Examples of cloned FAAHs include various mammalian FAAH such as, pig FAAH, rodent FAAH (*e.g.*, mouse FAAH and rat FAAH), and human FAAH. DNA sequences encoding FAAH and polypeptide sequences of various FAAHs are included in the appended Sequence Listing.

15 FAAH may be purified by standard methods in the art. The FAAH preparation may be in association with cell membranes or artificial membranes, or may be substantially free of cellular material.

Throughout the specification, reference is made to certain publications and patents. The entireties of each of these references is incorporated herein and forms a  
20 part of this disclosure.

## EXAMPLES

### Example 1

Radiolabeled anandamide [1-<sup>3</sup>H-ethanolamine] was obtained from American Radiolabeled Chemicals (10-20 Ci/mmol, catalog number ARC-626; St. Louis, Missouri, USA). Anandamide [arachidonyl-5,6,8,9,11,12,14,15-<sup>3</sup>H] was obtained from Perkin Elmer (160-240 Ci/mmol, catalog number NET-1073, Boston, Massachussets, USA), as was radiolabeled arachidonic acid [5,6,8,9,11,12,14,15-<sup>3</sup>H (N)] (180-240 Ci/mmol, catalog number NET298Z). Radiolabeled ethanolamine ([2-<sup>14</sup>C]Ethan-1-ol-2-amine hydrochloride) was purchased from Amersham Pharmacia Biotech (55 mCi/mmol, catalog number CFA329). Methyl arachidonyl fluorophosphate (MAFP) and oleyl trifluoromethyl ketone (OTFMK) were obtained from Cayman Chemical, (Catalog number 70660 and 6260, respectively; Ann Arbor, Michigan, USA). Activated charcoal was from Aldrich Chemical, Milwaukee, USA. Arachidonic acid, anandamide, oleic acid, oleamide, phenylmethylsulfonyl fluoride and CuSO<sub>4</sub> were from Sigma, St. Louis, Missouri, USA.

T84 human colorectal carcinoma cells (catalog number CCL-248, American Tissue Culture Collection, Manassas, Virginia, USA) were identified as expressing human FAAH based on gene expression profiling of cell lines using DNA microchips (not shown). The cells were cultured in a 1:1 mixture of Ham's F-12 media and Dulbecco's Modified Eagle Medium (Invitrogen) with 5 % fetal bovine serum (HyClone), 50U/ml penicillin and 50µg/ml streptomycin (Invitrogen). The cells were harvested by scraping into PBS and pelleted in a clinical centrifuge at 1000 rpm. The resulting pellets were then stored at -80°C until needed.

T84 frozen pellets were homogenized in FAAH assay buffer (125mM Tris, 1mM EDTA, 0.2% Glycerol, 0.02% Triton X-100, 0.4mM Hepes, pH 9) (Boger *et al.*

(2000) *Proc. Natl. Acad. Sci. USA* 97:5044-5049) and diluted to a final protein concentration of 70 µg/ml. Unless otherwise indicated, the assay mixture consisted of 50 µl of the cell homogenate, 10 µl of the appropriate inhibitor, and 40 µl of 40 nM <sup>3</sup>H-AEA, added last, for a final tracer concentration of 16 nM. The reactions were  
5 originally done at 37°C for 30 min; but subsequent experiments indicated that the enzyme displayed good activity at room temperature, and experiments were performed at room temperature for 60 minutes unless otherwise indicated.

During the one hour incubation, 96-well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, Massachusetts, USA) were loaded with  
10 25 µl activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100 µl methanol. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL510410) were loaded with 100 µl MicroScint40 (catalog number 6013641, Packard Bioscience, Meriden, Connecticut, USA). After the one hour incubation, 60 µl of the reaction mix was transferred to the  
15 charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2,000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at room temperature for 1 hour before counting on a Hewlett  
20 Packard TopCount. For determination of K<sub>m</sub> values, 1 µM <sup>3</sup>H-AEA was combined with 30 µM unlabeled AEA and serial 2-fold dilutions were made.

Uncleaved <sup>3</sup>H-anandamide, as well as the unlabeled arachidonic acid, is absorbed by the charcoal. In contrast, the labeled <sup>3</sup>H- ethanolamine flows through the charcoal mini-columns into 96 well counting plates when a vacuum or centrifugation

is applied. The 96 well plates can then be read on a Hewlett Packard TopCount (Fig.2.)

***Charcoal selectively binds anandamide and arachidonic acid, but not***

***5 ethanolamine:***

Four different radioactive tracers were used to explore the binding characteristics of the charcoal used in the assay: two tritiated forms of anandamide (labeled either on the ethanolamine moiety; anandamide [1-  $^3\text{H}$ -ethanolamine], or on the arachidonic acid moiety; arachidonic acid [5,6,8,9,11,12,14,15- $^3\text{H}$  (N)] ), as well  
10 as tritiated arachidonic acid, and  $^{14}\text{C}$ -labeled ethanolamine. Specific amounts of these tracers were incubated with membrane preparations, added to the pre-washed charcoal and recovered by centrifugation, as described in the methods. The recovered radioactivity was counted and expressed as percentage of the amount added. As shown in Fig. 3, when no membranes were present, *i.e.*, there was no FAAH-mediated  
15 conversion of anandamide to arachidonic acid plus ethanolamine, neither of the two labeled forms of anandamide could be detected in the flow-through, indicating that the tracers were bound to the charcoal. Tritiated arachidonic acid was also absorbed onto the charcoal and could not be detected in the flowthrough. Of the four tracers used, only the  $^{14}\text{C}$ -ethanolamine could be recovered.

20 It is known that HeLa cells, a human carcinoma cell line, do not express FAAH (Ueda *et al.* (2000) *Chem.Phys.Lipids*. 108:107-121). Therefore, this cell line was used as a negative control, and to investigate the possible contribution of non-FAAH enzymes to the hydrolysis of anandamide. There was essentially no recovery of radioactivity after incubation of  $^3\text{H}$ -anandamide with HeLa cell membranes,  
25 confirming the absence of FAAH (Fig. 3).

When the tracers were incubated with membranes prepared from mouse liver or T84 cells, good recovery of radioactivity was found for the anandamide labeled on the N-terminus of the amide ( $^3\text{H}$ -ethanolamine), but not for the anandamide carrying the tritium label on the hydrocarbon chain of the fatty acid ( $^3\text{H}$ -AA). All experiments

5 consistently showed that anandamide and arachidonic acid, in contrast to ethanolamine, were absorbed onto the charcoal column. Therefore, when radiolabeled anandamide is incubated with a cell lysate containing FAAH the radioactivity recovered in the flow-through must be attributed to the radiolabeled ethanolamine. This experiment indicates that it is possible to separate anandamide and

10 ethanolamine using charcoal. Other products, such as SAX and C18 resin were also tested, but were less effective (not shown).

***Characterization of the FAAH assay:***

FAAH activity is found in a large variety of cells. In rodents, the liver, followed by the brain, seems to have the highest expression of FAAH, whereas in

15 humans, the expression is highest in the pancreas and brain, but lower in the liver (Ueda *et al.* (2000) *Chem.Phys.Lipids.* 108:107-121). The expression of human FAAH mRNA in T84 cells was found by expression profiling using DNA microarrays (not shown) and confirmed by subsequent experiments.

The signal output of the assay was determined to be linear in the range of

20 0.42-3.5  $\mu\text{g}$ /well T84 membrane. Since an embodiment of the invention is a HTS-compatible assay, it was verified that the reaction was linear over more than 1 hour at the amount of protein used. As shown in Figure 4 A, the rate of the reaction at room temperature was linear over a period of 90 minutes when 3.5  $\mu\text{g}$ /well protein was used. This experiment was performed both at room temperature and at 37°C, with the

25 enzyme being slightly more active at the higher temperature, as expected. For the



performance of HTS assays, an incubation period of 1 hour at room temperature and a protein amount of 3.5 µg/ well was chosen based on these results.

***Kinetic analysis of FAAH activity:***

Kinetic analyses of the hydrolysis of anandamide by FAAH in T84 human  
5 colorectal carcinoma cells demonstrated a  $K_m$  of  $1.1 \pm 0.17$  µM. (Fig. 4 B). This is close to the value that has been reported for human brain (2 µM, see Maccarrone *et al.* (Maccarrone *et al.* (1999) *Anal. Biochem.* 267:314-318)). Overall, the reported  $K_m$  values in the literature for FAAH reactions range widely, from 0.8 to 80 µM, depending on the tissue, species and method used (Fowler *et al.* (2001) *Biochem.*  
10 *Pharmacol.* 62:517-526). For instance, Desarnaud *et al.* (Desarnaud *et al.* (1995) *J. Biol. Chem.* 270, 6030-6035) found a  $K_m$  of 12.7 µM using rat brain microsomes. In the N18 mouse neuroblastoma cell line, the  $K_m$  was determined to be 9.0 µM (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86). Apart from species differences, the variability in these values has been ascribed to the observation that both the substrate  
15 and product of this enzyme can form micelles, which may affect the enzyme activity (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526).

***Validation of the FAAH assay using reference compounds:***

Several of the FAAH inhibitors that have been described in the literature were tested in the assay to validate its ability to identify inhibitors. Of the inhibitors that  
20 are commercially available, methyl arachidonyl fluorophosphate (MAFP), which is also an inhibitor of cytosolic phospholipase A<sub>2</sub>, is the most potent, with reported IC<sub>50</sub> values of 1-3 nM (Ueda *et al.* (2000) *Chem. Phys.Lipids* 108, 107-121; Deutsch *et al.* (1997) *Biochem. Pharmacol.* 53, 255-260). Its potency as an inhibitor of FAAH was confirmed with the determination of an IC<sub>50</sub> value of 0.8 nM.

Oleyl trifluoromethyl ketone, a transition-state inhibitor, has also been reported to be a potent inhibitor of FAAH, with an  $IC_{50}$  of 73.3 nM in the studies here presented, it was in the same range as the  $IC_{50}$  values of 28 - 41 nM found by Tiger *et al.* (2000; *Biochem. Pharmacol.* 59, 647-653).

5        Phenylmethanesulfonyl fluoride, an inhibitor of serine proteases, was shown to be an inhibitor of FAAH, although with a low potency. Its  $pIC_{50}$  for the inhibition of rat brain FAAH in another group was between 5.92 and 4.16, depending on the pH (Holt *et al.* (2001) *Br. J. Pharmacol.* 133, 513-520). At a concentration of 100  $\mu$ M, it abolished anandamide hydrolysis in N18 mouse neuroblastoma cells (Maurelli *et al.* 10 (1995) *FEBS Lett.* 377, 82-86). It was used at a concentration of 1.5 mM by Deutsch *et al.* (1993; *Biochem. Pharmacol.* 46, 791-796) to block FAAH activity in neuroblastoma and glial cells. At 25  $\mu$ M, it inhibited the hydrolysis of rat brain microsomal anandamide by 48 % (Desarnaud *et al.* (1995) *J. Biol. Chem.*, 270, 6030-6035). The  $IC_{50}$  value (16  $\mu$ M) obtained in this work thus corresponds well to the 15 numbers reported in the literature.

Finally, product inhibition was tested by using the FAAH products oleic acid and arachidonic acid. Maurelli *et al.* (1995; *FEBS Lett.* 377, 82-86) found that 100  $\mu$ M anandamide abolished the activity of FAAH. In this work, these compounds inhibited FAAH activity with  $IC_{50}$  values in the low micromolar range (Table 1).

20        These results confirm that the assay provides a robust method for the evaluation of FAAH activity. The assay was successfully validated using reference inhibitors. As the assay may be performed simultaneously in multiple reactions, such as in a 96 well plate, for example, the assay is adaptable for high-throughput screening of compound collections as well as natural product or combinatorial 25 libraries.

Table 1. Activity of known FAAH inhibitors in T84 membranes

COMPOUND	IC <sub>50</sub> (nM)	Literature (ref)
Methyl arachidonyl fluorophosphate	0.8 ± 0.7	2.5 <sup>(1)</sup> 1-3 <sup>(2)</sup>
Oleyl trifluoromethyl ketone	73.3 ± 19.8	39 <sup>(3)</sup> 24-41 <sup>(4)</sup>
Phenylmethylsulfonyl fluoride	15978 ± 8863	1200-69000 <sup>(5)</sup>
Arachidonic acid	931.4 ± 255.4	-
Oleic acid	1936 ± 401	-

The average ± S.E. of values obtained in 2-5 experiments, each done in triplicate, is given.

The numbers in the column on the right refer to literature data. References : (1) : Deutsch *et al.* Biochem. Pharmacol. 1997, 53: 255-260. (2) : Ueda *et al.* Chem. Phys.Lipids 2000, 108 : 107-121. (3) Fowler *et al.* Br. J. Pharmacol. 2000, 131: 498-504. (4) Tiger *et al.* Biochem. Pharmacol. 2000, 59:647-653. (5) Holt *et al.* Br. J. Pharmacol. 2001, 133: 513-520.

The foregoing description, examples and accompanying figures generally describe the invention. The description is for purposes of providing illustrations; the present invention is not to be limited by the specific embodiments described herein. One of skill in the art will appreciate that various modifications of the invention may be made in addition to those described herein. Such modifications are intended to fall within the scope of the appended claims.

Fig FAAH Nucleic Acid Sequence (SEQ ID NO:1)

```

cggtcctcgg tgggagatca tgggtgcagga agaactgtgg gctgcgttct
ccggccccctc cgggggttgcc ctggcctgct gcttgggtggc agcggccttg
gccctgcggtt ggtccagtcg ccggatggcg cggggcgcg cggcccgggc
gcgacagagg cagcaagcgg ccctggagac catggacaag gcggcgcgagc
gcttccgggt ccagaacccc gatctggact cggagatgct gctggccctg
ccactgcctc agctggtaca gaaggtacga agtggggagc tgtctccaga
ggctgtgctc ttttccctacc tgcaaaaaggc ctgggaagtg aacagagggg
ccaactgcgt gaccacctac ctggcagact gtgaggctca gctgtgccag
gcgcccgggc agggcctgct ctacgggtgc cccgtcagcc tcaaggagtg
cttcagctgc aagggccatg actccacgct gggcttgagc cggaaccagg
ggacaccagc agaatgtgac tgcgtggtgg tgcagggtgct gaaactgcag
ggtgctgtgc ctttcgtgca caccaacgtc cccagtgcca tggtcagcta
tgactgcagt aacccccctt ttggccagac caggaaccca tggatgtcgt
ccaagagccc gggcggtctc tcgggaggtg agggggccct cattgtctgt
ggaggctccc cactgggctt aggcacgcac atcgggggca gcatccgctt
tccctccgcc ttctgtggca tctgcggcat caaaccacg ggaaccgca
tcagcaagag tggctctgaag ggctctgtct atggacaggt agcagtgcag
ctctcagtgg gccccatggc gcgggacgtg gagagcctgg ccctgtgcct
gcgtgcgctg ctgtgcgaag acatgttccg cctggacccc acgggtgcctc
ccctgccctt caacgaggag gtctacgcaa gctctcggcc cctgcgtgtc
gggtattatg agaccgacaa ctacaccatg cccacgccgg ccatgaggcg
ggccctgctg gagaccaagc ggagccttga ggctgcgggc cacacgtga
ttcccttctt gccggccaac atacccacg ctctggaggc cctgtcaacg
ggcgggctct tcagtgatgg tgggaagagg ttgctacaga acttcgaagg
cgattacgtg gactcctgct taggggacct gatctcaatt ctgaggctgc
ccaaatggct taaaggactg ctggctttca tgctgaggcc tctgtccca
aggttggcag gctttctcag cagcctgagg cctcggtcgg ctggaaagct
ctgggaactg cagcacgaga ttgagatgta ccgtcactcc gtgattgccc
agtggcgagc gctggacctg gatgtggtgc taacccccat gctgagccct
gccctagact tgaatgcccc aggcgaaggc acagggggcg tcagctacac
gctgctctac aactgcctgg acttccccgc gggggtggtg cctgtcacca
cggtgactgc cgaggacgag gccagatgg agcattacaa gggctacttt
ggggacattt gggacaaggt ggtgcagaag gccatgaaga ggagcgtggg
gctgcctgtg gccgtgcagt gtgtggtctt gccctggcag gaggagctgt
gtttgcgggt catgcgggag gtggagcgac tgatggctcc tgggcggcag
ccctcctgac cgtgcccgc cggccccccc aggacctgag acccactgga
tccgcgcccc gcggagtcag gacacaactg ccaccgtgca agaaaatgtt
caacctcagg cagaggcttc ccggtctctc cccctcgccc ctgccagaag
cccagaacca ctgagtctgg accttgcctt tcccggtggtc cctgctctgc
cctgaccccc ccaatgtggc agctagtggg tatgacatgg caaaggcccc
ccaaccgtca aaaaccggtt cctggtctcc atactttctg gcagtcgttg
ttagggcagt gggggttggg gacctgacct tctggaaccc gactccagcc
atgtccgtct cgtgctgcag aagcttctct ggtcctcgtc actcacgggc
agacaccggc ttctccgagt gggccttgca gccaggact tcaccccgcc
gccccagcc taagccctac tttgcgaggc attgtcttct ctccctgcct
ctgctgaggg tgccctttct gctcctctac cattaaatcc tttgaggccc

```

## Fig FAAH Amino Acid Sequence (SEQ ID NO:2)

MVQEELWAAF	SGPSGVALAC	CLVAAALALR	WSSRRMARGA	AARARQRQQA
ALETMDKAAQ	RFRLQNPDL	SEMLLALPLP	QLVQKVRSGE	LSPEAVLFSY
LQKAWEVNRG	TNCVTTYLAD	CEAQLCQAPG	QGLLYGVPVS	LKECFSCCKGH
DSTLGLSRNQ	GTPAECDCVV	VQVLKLQGA	PFVHTNVPQS	MFSYDCSNPL
FGQTTNPWMS	SKSPGGSSGG	EGALIAAGGS	PLGLGTDIGG	SIRFPSAFCG
ICGIKPTGNR	ISKSGLKGSV	YGQVAVQLSV	GPMARDVESL	ALCLRALLCE
DMFRLDPTVP	PLPFNEEVYA	SSRPLRVGY	ETDNYTMPTP	AMRRALLETK
RSLEAAGHTL	IPFLPANIPH	ALEALSTGGL	FSDGGKRLLQ	NFEGDYVDSC
LGDLSILRL	PKWLKGLLAF	MLRPLLRLA	GFLSSLRPRS	AGKLWELQHE
IEMYRHSVIA	QWRALDLDV	LTPMLSPALD	LNAPGKATGA	VSYTLLYNCL
DFPAGVVPVT	TVTAEDAEQM	EHYKGYFGDI	WDKVVQKAMK	RSVGLPVAVG
CVALPWQEEL	CLRFRMREVER	LMAAGRQPS		

## Mouse FAAH Nucleic Acid Sequence (SEQ ID NO:3)

atgggtgctga	gcgaagtgtg	gaccgcgctg	tctggactct	ccgggggttg
cctagcctgc	agcttgctgt	cggcggcggt	ggtcctgcga	tggaccagga
gccagaccgc	ccggggcgcg	gtgaccagg	cgcggcagaa	gcagcgagcc
ggcctggaga	ccatggacaa	ggcgggtgcag	cgcttccggc	tgcagaatcc
tgacctggat	tcagaggcct	tgctggctct	gcccctgctc	caactggtac
agaagttaca	gagtggggaa	ctgtccccag	aagctgtgct	ctttacctac
ctgggaaagg	cctgggaagt	gaacaaagg	accaactgtg	tgacctccta
tctgactgac	tgtgagactc	agctgtccca	ggccccacgg	cagggcctgc
tctatggcgt	ccccgtgagc	ctcaaggaa	gcttcagcta	caagggccat
gcttcacac	tgggcttaag	tttgaacgag	ggtgtgacat	cggagagtga
ctgtgtgggt	gtgcaggtac	tgaagctgca	gggagctgtg	ccctttgtgc
acaccaacgt	ccccagtc	atgctaagct	atgactgcag	taacccccctc
tttggccaga	ccatgaaccc	gtggaagccc	tccaagagtc	caggagggttc
ctcagggggg	gagggggctc	tcattggatc	tggaggctcc	cctctggggt
taggcactga	catcggcggc	agcatccgg	tcccttctgc	cttctgtggc
atctgtggcc	tcaagcctac	tgggaaccgc	ctcagcaaga	gtggcctgaa
gagctgtggt	tatggacaga	cagcagtgc	gctttctgtt	ggccccatgg
cacgggatgt	ggatagcctg	gcattgtgca	tgaagccct	actttgtgag
gatttgttcc	gcttggaactc	caccatcccc	cccttgccct	tcaggaggga
gatctacaga	agttctcgac	cccttcgtgt	gggatactat	gaaactgaca
actacaccat	gcccactcca	gccatgagga	gggctgtgat	ggagaccaag
cagagtctcg	aggctgctgg	ccacacgctg	gtccccttct	taccaaacaa
cataccttat	gccctggagg	tcctgtcggc	aggtgggctg	ttcagtgatg
gtggctgctc	ttttctccaa	aacttcaaag	gcgactttgt	ggatccctgc
ttgggggacc	tggcttagt	gctgaagctg	cccagggtgt	ttaaaaaact
gctgagcttc	ctgctgaagc	ctctgtttcc	tcggctggca	gcctttctca
acagtatgtg	tcctcggtca	gccgaaaagc	tgtgggaact	gcagcatgag
attgagatgt	atcgccagtc	cgctattgcc	cagtggagg	caatgaactt
ggacgtgggt	ctaaccacca	tgtctgggtcc	tgctctggat	ttgaacacac
cgggcagagc	cacaggggt	atcagctaca	ctgttctcta	taactgcctg
gacttccctg	cgggggtgtg	gcctgtcacc	actgtgaccg	ctgaggacga
tgcccagatg	gaacactaca	aaggctactt	tggggatatg	tgggacaaca
ttctgaagaa	gggcatgaaa	aagggtatag	gcctgcctgt	ggctgtgcag
tgcgtggctc	tgccctggca	ggaagagctg	tgtctgcggt	tcatgcggga

ggtggaacgg ctgatgaccc ctgaaaagcg gccatcttga

Mouse FAAH Amino Acid Sequence (SEQ ID NO:4)

MVLSEVWTAL SGLSGVCLAC SLLSAAVVLR WTRSQTARGA VTRARQKQRA  
 GLETMDKAVQ RFRLQNPDL D SEALLALPLL QLVQKLSGE LSPEAVLFTY  
 LGKAWENVKG TNCVTSYLT D CETQLSQAPR QGLLYGVPVS LKECF SYKGH  
 ASTLGLSLNE GVTSESDCVV VQVLKLQGA V PFVHTNVPQS MLSYDCSNPL  
 FGQTMNPWK P SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG  
 ICGLKPTGNR LSKSGLKSCV YGQTAVQLSV GPMARDVDSL ALCKMALLCE  
 DLFRLDSTIP PLPFREEIYR SSRPLRVGY ETDNYTMPTP AMRRVAMETK  
 QSLEAAGHTL VPFLPNNIPY ALEVLSAGGL FSDGGCSFLQ NFKGDFVDPC  
 LGDLVLVLKL PRWFKLLSF LLKPLFPRLA AFLNSMCPRS AEKLWELQHE  
 IEMYRQSVIA QWKAMNLDVV LTPMLGPALD LNTPGRATGA ISYTVLYNCL  
 DFPAGVVPVT TVTAEDDAQM EHYKGYFGDM WDNILKKG MK KGIGLPVAVQ  
 CVALPWQEEL CLRFMREVER LMTPEKRPS

Rat FAAH Nucleic Acid Sequence (SEQ ID NO:5)

ggtttgtgcg agccgagttc tctcgggtgg cggtcggctg caggagatca  
 tgggtgctgag cgaagtgtgg accacgctgt ctgggggtctc cggggtttgc  
 ctagcctgca gcttgttgtc ggcggcggtg gtcctgcat ggaccggcg  
 ccagaaggcc cggggcgcg cgaccagggc gcggcagaag cagcgagcca  
 gcctggagac catggacaag gcggtgcagc gcttccggct gcagaatcct  
 gacctggact cggaggcctt gctgacctg cccctactcc aactggtaca  
 gaagttagac agtgagagc tgtccccaga ggctgtgtt tttacttacc  
 tgggaaaggc ctgggaagt aacaaaggga ccaactgcgt gacctctat  
 ctgaccgact gtgagactca gctgtcccag gccccacggc agggcctgct  
 ctatggtgtc cctgtgagcc tcaaggaatg cttcagctac aagggccacg  
 actccacact gggcttgagc ctgaatgagg gcatgccatc ggaatctgac  
 tgttgtgtgg tgcaagtgt gaagctgcag ggagctgtg cctttgtgca  
 taccaatgtc cccagtgcca tgtaagctt tgactgcagt aacctctct  
 ttggccagac catgaacca tggaagtcct ccaagagccc aggaggttcc  
 tcaggggggtg agggggctct cattggatct ggaggttccc ctctgggttt  
 aggcactgac attggcgga gcatccggtt cccttctgcc ttctgcggca  
 tctgtggcct caagcctact ggcaaccgcc tcagcaagag tggcctgaag  
 ggctgtgtct atggacagac ggcagtgcag ctttctcttg gccccatggc  
 ccgggatgtg gagagcctgg cgctatgcct gaaagctcta ctgtgtgagc  
 acttgttcac cttggacct accgtgcctc ccttgccctt cagagaggag  
 gtctatagaa gttctagacc cctgcgtgtg gggactatg agactgacaa  
 ctataccatg cccagcccag ctatgaggag ggctctgata gagaccaagc  
 agagacttga ggctgctggc cacacgctga ttcccttctt acccaacaac  
 ataccctacg ccctggaggt cctgtctgcg ggcggcctgt tcagtgaagg  
 tggccgcagt tttctccaaa acttcaaagg tgactttgtg gatccctgct  
 tgggagacct gatcttaatt ctgaggctgc ccagctggtt taaaagactg  
 ctgagcctcc tgctgaagcc tctgtttcct cggctggcag cctttctcaa  
 cagtatgcgt cctcggtcag ctgaaaagct gtggaaactg cagcatgaga  
 ttgagatgta tcgccagtct gtgattgccc agtggaagc gatgaacttg  
 gatgtgctgc tgaccccat gttgggcctt gctctggatt tgaacacacc  
 gggcagagcc acaggggcta tcagctacac cgttctctac aactgcctgg  
 acttccctgc gggggtggtg cctgtcacca ctgtgaccgc cgaggacgat

```

gccagatgg aactctacaa aggtacttt ggggatatct gggacatcat
cctgaagaag gccatgaaaa atagtgtcgg tctgcctgtg gctgtgcagt
gcgtggctct gccctggcag gaagagctgt gtctgaggtt catgcgggag
gtggaacagc tgatgacccc tcaaaagcag ccacgtgag ggtcgttcat
ccgccagctc tggaggacct aaggcccatg cgctgtgcac tgtagcccca
tgtattcagg agccaccacc cacgaggga cggccagcac agggaagagg
tgtctacctg cctctcccctg gactcctgca gccacaacca agtctggacc
ttcctccccg ttatggtcta ctttccatcc tgattcccctg ctttttatgg
cagccagcag gaatgacgtg ggccaaggat caccaacatt caaaaacaat
gcgtttatct attttctggg tatctccatt agggccctgg gaaccagagt
gctgggaagg ctgtccagac cctccagagc tggctgtaac cacatcactc
tcctgtctca aagcctccct agttctgtca cccacaagat agacacaggg
acatgtcctt ggcacttgac tcctgtcctt cctttcttat tcagattgac
cccagccttg atggaccctg cccctgcact tccttcctca gtccacctct
ctgccgacac gcccttttta tggctcctct atttgttggt gagacaaggt
ttctctcagt agccctggct gtccaggacc tcaactctgta gatgaggctg
gctttcaact cacaaggctg cctgcctggg tgctgggatt aaaggcgtat
gccaccacaa agaaaaaaaa aa

```

## Rat FAAH Amino Acid Sequence (SEQ ID NO:6)

```

MVLSEVWTTL SGVSGVCLAC SLLSAAVVLR WTGRQKARGA ATRARQKQRA
SLETMDKAVQ RFRLQNPDL D SEALLTLPLL QLVQKLQSGE LSPEAVFFTY
LGKAWEVNKG TNCVTSYLT D CETQLSQAPR QGLLYGVFVS LKECFYSYKGH
DSTLGLSLNE GMPSESDCV V VQVLKLQGA V PFVHTNVPQS MLSFDCSNPL
FGQTMNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG
ICGLKPTGNR LSKSGLKGC V YGQTAVQLSL GPMARDVESL ALCLKALLCE
HLFTLDPTVP PLPFREEVY R SSRPLRVGY ETDNYTMPSP AMRRALIETK
QRLEAAGHTL IPFLPNNIP Y ALEVLSAGGL FSDGGRSFLQ NFKGDFVDPC
LGDILILIRL PSWFKRLSL L LLKPLFPRLA AFLNSMRPRS AEKLWKLQHE
IEMYRQSVIA QWKAMNLDV L LTPMLGPALD LNTPGRATGA ISYTVLYNCL
DFPAGVVPVT TVTAEDDAQ M ELYKGYFGDI WDIILKKAMK NSVGLPVAVQ
CVALPWQEE L CLRFMREVE Q LMT PQKQPS

```

## Human FAAH Nucleic Acid Sequence (SEQ ID NO:7)

```

tgccggggcgg taggcagcag caggctgaag ggatcatggt gcagtacgag
ctgtggggccg cgctgcctgg cgctccggg gtgcctctgg cctgctgctt
cgtggcgccg gccgtggccc tgcgtgggtc cgggcgcggg acggcgcggg
gcgcgggtggt ccgggcgcga cagaagcagc gagcgggcct ggagaacatg
gacagggcggt cgagcgctt ccggctccag aaccagacc tggactcaga
ggcgtgcta gccctgccc tgcctcagct ggtgcagaag ttacacagta
gagagctggc ccctgaggcc gtgctcttca cctatgtggg aaaggcctgg
gaagtgaaca aagggaccaa ctgtgtgacc tcctatctgg ctgactgtga
gactcagctg tctcaggccc caaggcaggg cctgctctat ggcgctccctg
tgagcctcaa ggagtgttc acctacaagg gccaggactc cacgctgggc
ttgagcctga atgaaggggt gccggcgagg tgcgacagcg tagtggtgca
tgtgctgaag ctgcagggtg ccgtgccctt cgtgcacacc aatgttccac
agtccatgtt cagctatgac tgcagtaacc ccctctttgg ccagacogtg
aaccatgga agtcctccaa aagcccaggg ggctcctcag ggggtgaagg
ggccctcatc ggtctggag gctccccct gggcttaggc actgatatcg

```

```

gaggcagcat ccgcttcccc tcctccttct gcggcatctg cggcctcaag
cccacaggga accgcctcag caagagtggc ctgaagggct gtgtctatgg
acaggaggga gtgcgtctct ccgtggggcc catggcccgg gacgtggaga
gcctggcact gtgcctgcga gccctgctgt gcgaggacat gttccgcttg
gacccactg tgcctccctt gcccttcaga gaagaggtct acaccagctc
tcagcccctg cgtgtggggt actatgagac tgacaactat accatgccct
ccccggccat gaggcggggc gtgctggaga ccaaacagag ccttgaggct
gcggggcaca cgctggttcc cttcttgcca agcaacatac cccatgctct
ggagaccctg tcaacagggt ggctcttcag tgatggtggc cacaccttc
tacagaactt caaaggtgat ttcgtggacc cctgcctggg ggacctggtc
tcaattctga agcttcccca atggcttaaa ggactgctgg ccttcctggt
gaagcctctg ctgccaaggc tgtcagcttt cctcagcaac atgaagtctc
gttcggctgg aaaactctgg gaactgcagc acgagatcga ggtgtaccgc
aaaaccgtga ttgcccagtg gagggcgctg gacctggatg tgggtctgac
ccccatgctg gccctgctc tggacttgaa tgccccaggc agggccacag
gggccgtcag ctacactatg ctgtacaact gcctggactt ccctgcaggg
gtggtgcctg tcaccacggt gactgctgag gacgaggccc agatggaaca
ttacaggggc tactttgggg atatctggga caagatgctg cagaagggca
tgaagaagag tgtgggggctg ccggtggccg tgcagtgtgt ggctctgccc
tggcaagaag agttgtgtct gcggttcatg cgggaggtgg agcgactgat
gaccctgaa aagcagtcac cctgatggct ctggctccag aggacctgag
actcacactc tctgcagccc agcctagtca gggcacagct gccctgctgc
cacagcaagg aaatgtcctg catggggcag aggcctccgt gtcctctccc
ccaacccct gcaagaagcg ccgactccct gagtctggac ctccatccct
gctctggtcc cctctcttcg tcctgatecc tccaccccca tgtggcagcc
catgggtatg acataggcca aggcccaact aacagtcaag aaacaaaaaa
aaaaaaaaaa aaa

```

## Human FAAH Amino Acid Sequence (SEQ ID NO:8)

```

MVQYELWAAL PGASGVALAC CFVAAVALR WSGRRTARGA VVRARQKQRA
GLENMDRAAQ RFRLQNPDL D SEALLALPLP QLVQKLHSRE LAPEAVLFY
VGKAWEVNKG TNCVTSYLAD CETQLSQAPR QGLLYGVPVS LKECFYKQG
DSTLGLSLNE GVPAECDSVV VHVLKLQGA V PFVHTNVPQS MFSYDCSNPL
FGQTVNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSSFCG
ICGLKPTGNR LSKSGLKGC V YGQEA VRLSV GPMARDVESL ALCLRALLCE
DMFRLDPTVP PLPFREEVYT SSQPLRVGY ETDNYTMPSP AMRRAVLETK
QSLEAAGHTL VPFLPSNIPH ALETLS TGGGL FSDGGHTFLQ NFKGDFVDPC
LGDLSILKL PQWLKGLLAF LVKPLL PRLS AFLSNMKSRS AGKLWELQHE
IEVYRKTVIA QWRALDL DVV LTPMLAPALD LNAPGRATGA VSYTMLYNCL
DFPAGVVPVT TVTAEDEAQM EHYRGYFGDI WDKMLQKGMK KSVGLPVA VQ
CVALPWQEEL CLRFMREVER LMTPEKQSS

```



What is claimed is:

1. A method of assaying the activity of a fatty acid amide hydrolase comprising the steps of:
  - combining a sample suspected of containing a fatty acid amide hydrolase, with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture;
  - incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;
  - contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex;
  - separating the bound labeled complex from the incubated reaction mixture;
  - and
  - determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.
2. The method of claim 1 wherein the sample comprises biological membranes, lipid bilayers, or micelles.
3. The method of claim 1 wherein the substrate is an endocannabinoid, a fatty acid ethanolamide, a fatty acid primary amide, an endocannabinoid analog, a fatty acid ethanolamide analog, or a fatty acid primary amide analog.
4. The method of claim 1 wherein the substrate is anandamide.

5. The method of claim 1 wherein the substrate is oleamide.
6. The method of claim 1 wherein the substrate is 2-arachidonoylglycerol.
7. The method of claim 1 wherein the substrate is labeled with a radioisotope.
8. The method of claim 7 wherein the radioisotope is  $^3\text{H}$  or  $^{14}\text{C}$ .
9. The method of claim 1 wherein the substrate is labeled with a fluorescent label.
10. The method of claim 1 wherein the selective binding material comprises carbon.
11. The method of claim 10 wherein the selective binding material is activated charcoal.
12. The method of claim 11 wherein the activated charcoal comprises a filter.
13. The method of claim 1 wherein the selective binding material binds the labeled substrate but not the labeled product.
14. The method of claim 1 wherein the separating step comprises filtration, gravity settling or centrifugation.

15. The method of claim 1 wherein the determining step is performed via liquid scintillation counting or by measurement of fluorescence energy.
16. The method of claim 1 conducted in a multiwell plate.
17. The method of claim 1 comprising at least a portion of a high throughput screening program.
18. The method of claim 1 wherein the method is conducted in conjunction with a drug discovery effort.
19. A method of identifying a compound that modulates the activity of a fatty acid amide hydrolase comprising the steps of:
  - comparing the activity of a fatty acid amide hydrolase as assayed by the method of claim 1, in the presence and in the absence of a test compound added to the reaction mixture;
  - wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.
20. The method of claim 19 wherein the test compound is selected from a library of compounds.
21. The method of claim 19 wherein the test compound inhibits the activity of the fatty acid amide hydrolase activity.

22. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 5%.
23. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 20%.
24. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 50%.
25. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 80%.
26. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 95% or more.
27. The method of claim 21 wherein said test compound increases said fatty acid amide hydrolase activity.
28. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 5%.
29. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 30%.

30. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 50%.
31. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 70%.
32. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 100%.
33. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased between about two-fold to about ten-fold.
34. The method of claim 19, which comprises the use of a multi-well plate.
35. The method of claim 19 conducted in a multiwell plate.
36. The method of claim 19 comprising at least a portion of a high throughput screening.
37. The method of claim 19 wherein the method is conducted in conjunction with a drug discovery effort.
38. The method of claim 1 wherein said fatty acid amide hydrolase is a mammalian fatty acid amide hydrolase.

39. The method of claim 38 wherein said fatty acid amide hydrolase is a porcine fatty acid amide hydrolase.
40. The method of claim 38 wherein said fatty acid amide hydrolase is a rodent fatty acid amide hydrolase.
41. The method of claim 38 wherein said fatty acid amide hydrolase is a murine fatty acid amide hydrolase.
42. The method of claim 41 wherein said fatty acid amide hydrolase is a rat fatty acid amide hydrolase.
43. The method of claim 41 wherein said fatty acid amide hydrolase is a mouse fatty acid amide hydrolase.
44. The method of claim 38 wherein said fatty acid amide hydrolase is a human fatty acid amide hydrolase.
45. A method for determining altered fatty acid amide hydrolase activity in a patient comprising:
- obtaining a sample containing cells from the patient;
  - lysing the cells to form a cell lysate;
  - combining the cell lysate with a labeled substrate of fatty acid amide hydrolase, to form a reaction mixture;

incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;

contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex;

separating the bound labeled complex from the incubated reaction mixture;

determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and

comparing the activity of the sample from the patient with the activity of a to a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

46. The method of claim 45 wherein said patient is female.

47. The method of claim 46 wherein the female is pregnant or is seeking fertility treatment.

48. The method of claim 45 wherein the sample comprises blood, tissue or body fluid.

49. The method of claim 46 wherein the sample comprises lymphocytes.


50. The method of claim 45 wherein the cells are homogenized.

51. The method of claim 45 wherein the fatty acid amide hydrolase activity present in the cell lysate is partially or substantially purified from the sample.
52. The method of claim 45 wherein the predetermined determined value is from a control assay, a prior or subsequent sample from the patient, a sample from a normal individual, a sample from another patient, a standard FAAH, or a predetermined value.




1/4


Step 1 : incubate  $^3\text{H}$ -anandamide  
with FAAH-containing membranes




FAAH



Step 2 : load on charcoal-  
filled filterplates



Step 3 : centrifuge



Step 4 : add scintillant to flow-through  
and count




FIG 1

2/4





FIG 2

3/4

**FIG 3**

4/4




FIG 4A




FIG 4B

WO 2004/037371

## SEQUENCE LISTING

<110> Barbier, Ann Johanna  
Wilson, Sandy J,  
Mazur, Curt

<120> Assay for Determining the Activity of Fatty Acid Amide Hydrolase

<130> PRI0002

<160> 8

<170> PatentIn version 3.1

<210> 1  
<211> 2300  
<212> DNA  
<213> Sus scrofa

<400> 1  
cggtcctcgg tgggagatca tgggtgcagga agaactgtgg gctgcgttct ccggcccctc 60  
cggggttgcc ctggcctgct gcttgggtggc agcggccttg gccctgcgtt ggtccagtcg 120  
ccggatggcg cggggcgcg cggcccgggc gcgacagagg cagcaagcgg ccctggagac 180  
catggacaag gcggcgagc gcttccggct ccagaacccc gatctggact cggagatgct 240  
gctggccctg ccaactgcctc agctggtaca gaaggtacga agtggggagc tgtctccaga 300  
ggctgtgctc ttttctacc tgcaaaaggc ctgggaagtg aacagagggg ccaactgcgt 360  
gaccacctac ctggcagact gtgaggctca gctgtgccag gcgcccgggc agggcctgct 420  
ctacggtgct cccgtcagcc tcaaggagtg cttcagctgc aagggccatg actccacgct 480  
gggcttgagc cggaaccagg ggacaccagc agaatgtgac tgcgtggtgg tgcagggtgct 540  
gaaactgcag ggtgctgtgc ctttcgtgca caccaacgtc cccagtcga tgttcagcta 600  
tgactgcagt aaccccctct ttggccagac cacgaaccca tggatgtcgt ccaagagccc 660  
gggcggtccc tcgggaggtg agggggccct cattgctgct ggaggtccc cactgggctt 720  
aggcaccgac atcgggggca gcatccgctt tccctccgcc ttctgtggca tctgcggcat 780  
caaaccacg gggaaccgca tcagcaagag tggcttgaag ggctctgtct atggacaggt 840  
agcagtgcag ctctcagtgg gcccattggc gcgggacgtg gagagcctgg ccctgtgcct 900  
gcgtgcgctg ctgtgcgaag acatgttccg cctggacccc acggtgcctc ccctgcctt 960  
caacgaggag gtctacgcaa gctctcggcc cctgcgtgct gggattatg agaccgacaa 1020  
ctacaccatg cccacgccgg ccatgaggcg ggccctgctg gagaccaagc ggagccttga 1080  
ggctgcgggc cacacgtga ttcccttcct gccggccaac ataccccacg ctctggaggc 1140  
cctgtcaacg ggccggctct tcagtgtggt tgggaagagg ttgctacaga acttcgaagg 1200  
cgattacgtg gactcctgct taggggacct gatctcaatt ctgaggctgc ccaaattggct 1260  
taaaggactg ctggctttca tgctgaggcc tctgtcccca aggttggcag gctttctcag 1320  
cagcctgagg cctcggtcgg ctggaaagct ctgggaactg cagcacgaga ttgagatgta 1380  
ccgtcactcc gtgattgccc agtggcgagc gctggacctg gatgtggtgc taaccccat 1440  
gctgagccct gccctagact tgaatgcccc aggcaaggcc acaggggccg tcagctacac 1500  
gctgctctac aactgcctgg acttccccgc ggggggtggtg cctgtcacca cggtgactgc 1560

cgaggacgag gccagatgg agcattacaa gggctacttt ggggacattt gggacaaggt 1620  
 ggtgcagaag gccatgaaga ggagcgtggg gctgcctgtg gccgtgcagt gtgtggctct 1680  
 gccctggcag gaggagctgt gtttgcgggt catgcgggag gtggagcgac tgatggctcc 1740  
 tgggcggcag ccctcctgac cgctgcccgc ccggccccc aggacctgag acccactgga 1800  
 tccgcgcccc gcggagtcag gacacaactg ccaccgtgca agaaaatgtt caacctcagg 1860  
 cagaggcttc ccggtctctc cccctcgccc ctgccagaag ccagaaacca ctgagtctgg 1920  
 acctgtctct tcccgtggtc cctgctctgc cctgaccccg ccaatgtggc agctagtggg 1980  
 tatgacatgg caaaggcccc ccaaccgtca aaaaccggtt cctggtctct atactttctg 2040  
 gcagtcgttg ttagggcagt gggggttgga gacctgacct tctggaacct gactccagcc 2100  
 atgtccgtct cgtgctgcag aagcttctct ggtcctcgtc actcacgggc agacaccggc 2160  
 ttctccgagt gggccttgca gcccaggact tcaccccgcc gccccagcc taagccctac 2220  
 tttgcgaggc attgtcttct ctctgccct ctgctgaggg tgccctttct gctcctctac 2280  
 cattaaatcc tttgaggccc 2300

<210> 2  
 <211> 579  
 <212> PRT  
 <213> Sus scrofa

<400> 2

Met Val Gln Glu Glu Leu Trp Ala Ala Phe Ser Gly Pro Ser Gly Val  
1 5 10 15

Ala Leu Ala Cys Cys Leu Val Ala Ala Ala Leu Ala Leu Arg Trp Ser  
20 25 30

Ser Arg Arg Met Ala Arg Gly Ala Ala Ala Arg Ala Arg Gln Arg Gln  
35 40 45

Gln Ala Ala Leu Glu Thr Met Asp Lys Ala Ala Gln Arg Phe Arg Leu  
50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Met Leu Leu Ala Leu Pro Leu Pro  
65 70 75 80

Gln Leu Val Gln Lys Val Arg Ser Gly Glu Leu Ser Pro Glu Ala Val  
85 90 95

Leu Phe Ser Tyr Leu Gln Lys Ala Trp Glu Val Asn Arg Gly Thr Asn  
100 105 110

Cys Val Thr Thr Tyr Leu Ala Asp Cys Glu Ala Gln Leu Cys Gln Ala  
115 120 125

Pro Gly Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
130 135 140

Phe Ser Cys Lys Gly His Asp Ser Thr Leu Gly Leu Ser Arg Asn Gln  
145 150 155 160

Gly Thr Pro Ala Glu Cys Asp Cys Val Val Gln Val Leu Lys Leu  
165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe  
180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Thr Asn Pro Trp  
195 200 205

Met Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
210 215 220

Ile Ala Ala Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Ile Lys Pro  
245 250 255

Thr Gly Asn Arg Ile Ser Lys Ser Gly Leu Lys Gly Ser Val Tyr Gly  
260 265 270

Gln Val Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu  
275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg  
290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Asn Glu Glu Val Tyr Ala  
305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
325 330 335

Met Pro Thr Pro Ala Met Arg Arg Ala Leu Leu Glu Thr Lys Arg Ser  
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Ala Asn Ile  
355 360 365

Pro His Ala Leu Glu Ala Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly  
370 375 380

Gly Lys Arg Leu Leu Gln Asn Phe Glu Gly Asp Tyr Val Asp Ser Cys  
385 390 395 400

Leu Gly Asp Leu Ile Ser Ile Leu Arg Leu Pro Lys Trp Leu Lys Gly  
405 410 415

Leu Leu Ala Phe Met Leu Arg Pro Leu Leu Pro Arg Leu Ala Gly Phe  
420 425 430

Leu Ser Ser Leu Arg Pro Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln  
435 440 445

His Glu Ile Glu Met Tyr Arg His Ser Val Ile Ala Gln Trp Arg Ala  
450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ser Pro Ala Leu Asp  
465 470 475 480

Leu Asn Ala Pro Gly Lys Ala Thr Gly Ala Val Ser Tyr Thr Leu Leu  
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly  
515 520 525

Asp Ile Trp Asp Lys Val Val Gln Lys Ala Met Lys Arg Ser Val Gly  
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Ala Pro Gly Arg  
565 570 575

Gln Pro Ser

<210> 3  
<211> 1740  
<212> DNA  
<213> Mouse

<400> 3  
atggtgctga gcgaagtgtg gaccgcgctg tctggactct ccgggggttg cctagcctgc 60  
agcttgctgt cggcggcggt ggtcctgcga tggaccagga gccagaccgc ccggggcgcg 120  
gtgaccaggg cgcgcgagaa gcagcgagcc ggcctggaga ccatggacaa ggcggtgcag 180  
cgcttcgggc tgcagaatcc tgacctggat tcagaggcct tgctggctct gcccctgctc 240  
caactggtac agaagttaca gagtggggaa ctgtccccag aagctgtgct ctttacctac 300  
ctgggaaagg cctgggaagt gaacaaagg accaactgtg tgacctccta tctgactgac 360  
tgtgagactc agctgtccca ggccccacgg cagggcctgc tctatggcgt ccccgtagac 420  
ctcaaggaat gcttcagcta caagggccat gcttcacac tgggcttaag tttgaacgag 480  
ggtgtgacat cggagagtga ctgtgtggtg gtgcaggtac tgaagctgca gggagctgtg 540  
ccctttgtgc acaccaacgt ccccgagtc atgctaagct atgactgcag taaccccctc 600  
tttgccaga ccatgaaccc gtggaagccc tccaagagtc caggaggttc ctcagggggt 660  
gagggggctc tcattggatc tggaggctcc cctctgggtt taggcactga catcgcgggc 720



```

agcatccggt tcccttctgc cttctgtggc atctgtggcc tcaagcctac tgggaaccgc 780
ctcagcaaga gtggcctgaa gagctgtgtt tatggacaga cagcagtgca gctttctgtt 840
ggccccatgg cacgggatgt ggatagcctg gcattgtgca tgaaagccct actttgtgag 900
gatttgttcc gcttggactc caccatcccc cccttgcctc tcagggagga gatctacaga 960
agttctcgac cccttctgtt gggatactat gaaactgaca actacaccat gccactcca 1020
gccatgagga gggctgtgat ggagaccaag cagagtctcg aggctgtctg ccacacgctg 1080
gtcccccttct taccaaacia cataccttat gccctggagg tcctgtcggc aggtgggctg 1140
ttcagtgatg gtggctgctc ttttctccaa aacttcaaag gcgactttgt ggatccctgc 1200
ttgggggacc tggctcttagt gctgaagctg cccaggtggt ttaaaaaact gctgagcttc 1260
ctgctgaagc ctctgtttcc tcggctggca gcctttctca acagtatgtg tcctcgggtca 1320
gccgaaaagc tgtgggaact gcagcatgag attgagatgt atcgccagtc cgtcattgcc 1380
cagtgggaag caatgaactt ggacgtggtg ctaaccccca tgctgggtcc tgctctggat 1440
ttgaacacac cgggcagagc cacaggggct atcagctaca ctgttctcta taactgcctg 1500
gacttccctg cgggggtggt gcctgtcacc actgtgaccg ctgaggacga tgcccagatg 1560
gaacactaca aaggctactt tggggatatt tgggacaaca ttctgaagaa gggcatgaaa 1620
aagggtatag gcctgcctgt ggctgtgcag tgcgtggctc tgccctggca ggaagagctg 1680
tgtctgcggt tcatgcggga ggtggaacgg ctgatgacct ctgaaaagcg gccatcttga 1740

```

<210> 4  
 <211> 579  
 <212> PRT  
 <213> Mouse

<400> 4

Met Val Leu Ser Glu Val Trp Thr Ala Leu Ser Gly Leu Ser Gly Val  
1 5 10 15

Cys Leu Ala Cys Ser Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr  
20 25 30

Arg Ser Gln Thr Ala Arg Gly Ala Val Thr Arg Ala Arg Gln Lys Gln  
35 40 45

Arg Ala Gly Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu  
50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Leu  
65 70 75 80

Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val  
85 90 95

Leu Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
100 105 110

Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala

115	120	125
Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys		
130	135	140
Phe Ser Tyr Lys Gly His Ala Ser Thr Leu Gly Leu Ser Leu Asn Glu		
145	150	155
Gly Val Thr Ser Glu Ser Asp Cys Val Val Val Gln Val Leu Lys Leu		
165	170	175
Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu		
180	185	190
Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp		
195	200	205
Lys Pro Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu		
210	215	220
Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly		
225	230	235
Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro		
245	250	255
Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Ser Cys Val Tyr Gly		
260	265	270
Gln Thr Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Asp		
275	280	285
Ser Leu Ala Leu Cys Met Lys Ala Leu Leu Cys Glu Asp Leu Phe Arg		
290	295	300
Leu Asp Ser Thr Ile Pro Pro Leu Pro Phe Arg Glu Glu Ile Tyr Arg		
305	310	315
Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr		
325	330	335
Met Pro Thr Pro Ala Met Arg Arg Ala Val Met Glu Thr Lys Gln Ser		
340	345	350
Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Asn Asn Ile		
355	360	365
Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly		
370	375	380
Gly Cys Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys		
385	390	395
		400

Leu Gly Asp Leu\_Val Leu Val Leu Lys Leu Pro Arg Trp Phe Lys Lys  
405 410 415

Leu Leu Ser Phe Leu Leu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe  
420 425 430

Leu Asn Ser Met Cys Pro Arg Ser Ala Glu Lys Leu Trp Glu Leu Gln  
435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala  
450 455 460

Met Asn Leu Asp Val Val Leu Thr Pro Met Leu Gly Pro Ala Leu Asp  
465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu  
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly  
515 520 525

Asp Met Trp Asp Asn Ile Leu Lys Lys Gly Met Lys Lys Gly Ile Gly  
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys  
565 570 575

Arg Pro Ser

<210> 5  
<211> 2472  
<212> DNA  
<213> rattus rattus

<400> 5  
ggtttgtgcg agccgagttc tctcgggtgg cggtcggctg caggagatca tgggtctgag 60  
cgaagtgtgg accacgctgt ctgggggtctc cggggtttgc ctaccctgca gcttgttgtc 120  
ggcggcgggtg gtcctgcgat ggaccgggcg ccagaaggcc cggggcgcg cgaccagggc 180  
gcggcagaag cagcgagcca gcctggagac catggacaag gcggtgcagc gcttccggct 240  
gcagaatcct gacctggact cggaggcctt gctgaccctg cccctactcc aactggtaca 300  
gaagttacag agtggagagc tgtccccaga ggctgtgttc tttacttacc tgggaaaggc 360  
ctgggaagtg aacaaaggga ccaactgctg gacctctat ctgaccgact gtgagactca 420  
gctgtcccag gccccacggc agggcctgct ctatggtgtc cctgtgagcc tcaaggaatg 480  
cttcagctac aagggccacg actccacact gggcttgagc ctgaatgagg gcatgccatc 540

```

ggaatctgac tgtgtggtgg tgcaagtgtt gaagctgcag ggagctgtgc ctttctgtca 600
taccaatgtc cccaggtcca tgtaagctt tgactgcagt aacctctctt ttggccagac 660
catgaacca tggaagtcct ccaagagccc aggaggttcc tcagggggtg agggggctct 720
cattggatct ggaggttccc ctctgggttt aggcactgac attggcggca gcatccggtt 780
cccttctgcc ttctgcggca tctgtggcct caagcctact ggcaaccgcc tcagcaagag 840
tggcctgaag ggctgtgtct atggacagac ggcagtgcag ctttctcttg gccccatggc 900
ccgggatgtg gagagcctgg cgctatgcct gaaagctcta ctgtgtgagc acttgttcac 960
cttgaccct accgtgcctc ccttgccctt cagagaggag gtctatagaa gttctagacc 1020
cctgcgtgtg gggactactg agactgacaa ctataccatg ccagcccag ctatgaggag 1080
ggctctgata gagaccaagc agagacttga ggctgctggc cacacgctga ttcccttctt 1140
acccaacaac ataccctacg ccctggaggt cctgtctgcg ggcgccctgt tcagtgcagg 1200
tggccgcagt tttctccaaa acttcaaagg tgactttgtg gatccctgct tgggagacct 1260
gatcttaatt ctgaggctgc ccagctggtt taaaagactg ctgagcctcc tgctgaagcc 1320
tctgtttcct cggttgccag cctttctcaa cagtatgcgt cctcggtcag ctgaaaagct 1380
gtggaactg cagcatgaga ttgagatgta tcgccagtct gtgattgcc agtggaagc 1440
gatgaactg gatgtgctgc tgacccccat gttgggccct gctctggatt tgaacacacc 1500
gggcagagcc acaggggcta tcagctacac cgttctctac aactgcctgg acttccctgc 1560
gggggtggtg cctgtcacca ctgtgaccgc cgaggacgat gccagatgg aactctacaa 1620
aggctacttt ggggatattt gggacatcat cctgaagaag gccatgaaaa atagtgtcgg 1680
tctgcctgtg gctgtgcagt gcgtggctct gccctggcag gaagagctgt gtctgaggtt 1740
catgcgggag gtggaacagc tgatgacccc tcaaaagcag ccacgtgag ggtcgttcat 1800
ccgccagctc tggaggacct aaggcccatg cgctgtgcac tgtagcccca tgtattcagg 1860
agccaccacc cacgagggaa cgcccagcac agggaagagg tgtctacctg cctccctctg 1920
gactcctgca gccacaacca agtctggacc ttctccccc ttatggtcta ctttccatcc 1980
tgattccctg ctttttatgg cagccagcag gaatgacgtg ggccaaggat caccaacatt 2040
caaaaacaat gcgtttatct attttctggg tatctccatt agggccctgg gaaccagagt 2100
gctgggaagg ctgtccagac cctccagagc tggctgtaac cacatcactc tctgtctca 2160
aagcctccct agttctgtca cccacaagat agacacaggg acatgtcctt ggcacttgac 2220
tctgtcctt ctttcttat tcagattgac ccagccttg atggaccctg cccctgcact 2280
tccttctca gtccacctct ctgccgacac gcccttttta tggctcctct atttgttg 2340
gagacaaggt ttctctcagt agccctggct gtccaggacc tcaactctgta gatgaggctg 2400
gctttcaact cacaaggctg cctgcctggg tgctgggatt aaaggcgtat gccaccacaa 2460
agaaaaaaaa aa 2472

```

<210> 6  
<211> 579  
<212> PRT

<213> rattus rattus

&lt;400&gt; 6

Met Val Leu Ser Glu Val Trp Thr Thr Leu Ser Gly Val Ser Gly Val  
1 5 10 15

Cys Leu Ala Cys Ser Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr  
20 25 30

Gly Arg Gln Lys Ala Arg Gly Ala Ala Thr Arg Ala Arg Gln Lys Gln  
35 40 45

Arg Ala Ser Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu  
50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Thr Leu Pro Leu Leu  
65 70 75 80

Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val  
85 90 95

Phe Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
100 105 110

Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala  
115 120 125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
130 135 140

Phe Ser Tyr Lys Gly His Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu  
145 150 155 160

Gly Met Pro Ser Glu Ser Asp Cys Val Val Val Gln Val Leu Lys Leu  
165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu  
180 185 190

Ser Phe Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp  
195 200 205

Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro  
245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly  
260 265 270

Gln Thr Ala Val Gln Leu Ser Leu Gly Pro Met Ala Arg Asp Val Glu  
 275 280 285

Ser Leu Ala Leu Cys Leu Lys Ala Leu Leu Cys Glu His Leu Phe Thr  
 290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Arg  
 305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
 325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Leu Ile Glu Thr Lys Gln Arg  
 340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Asn Asn Ile  
 355 360 365

Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly  
 370 375 380

Gly Arg Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
 385 390 395 400

Leu Gly Asp Leu Ile Leu Ile Leu Arg Leu Pro Ser Trp Phe Lys Arg  
 405 410 415

Leu Leu Ser Leu Leu Leu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe  
 420 425 430

Leu Asn Ser Met Arg Pro Arg Ser Ala Glu Lys Leu Trp Lys Leu Gln  
 435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala  
 450 455 460

Met Asn Leu Asp Val Leu Leu Thr Pro Met Leu Gly Pro Ala Leu Asp  
 465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu  
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
 500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu Leu Tyr Lys Gly Tyr Phe Gly  
 515 520 525

Asp Ile Trp Asp Ile Ile Leu Lys Lys Ala Met Lys Asn Ser Val Gly  
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Gln Leu Met Thr Pro Gln Lys  
565 570 575

Gln Pro Ser

<210> 7  
<211> 2063  
<212> DNA  
<213> homo sapiens

<400> 7  
tgccgggagg taggcagcag caggctgaag ggatcatggt gcagtacgag ctgtggggccg 60  
cgctgccttg cgcctccggg gtcgcccttg cctgctgctt cgtggcggcg gccgtggccc 120  
tgcgctggtc cgggcgccgg acggcgccgg gcgcggtggt ccgggcgcga cagaagcagc 180  
gagcggggcct ggagaacatg gacagggcgg cgcagcgctt ccggctccag aaccagacc 240  
tggaactcaga ggcgctgcta gccctgcccc tgcctcagct ggtgcagaag ttacacagta 300  
gagagctggc ccctgaggcc gtgctcttca cctatgtggg aaaggccttg gaagtgaaca 360  
aagggaccaa ctgtgtgacc tcctatcttg ctgactgtga gactcagctg tctcaggccc 420  
caaggcaggg cctgctctat ggcgtccctg tgagcctcaa ggagtgttc acctacaagg 480  
gccaggactc cacgctgggc ttgagcctga atgaaggggt gccggcggag tgcgacagcg 540  
tagtggtgca tgtgctgaag ctgcagggtg ccgtgccctt cgtgcacacc aatgttccac 600  
agtccatggt cagctatgac tgcaagtaacc ccctcttttg ccagaccgtg aaccatgga 660  
agtcctccaa aagcccaggg ggctcctcag ggggtgaagg ggccctcacc gggctctggag 720  
gtccccccct gggcttaggc actgatatcg gaggcagcat ccgttcccc tcctccttct 780  
gcggcatctg cggcctcaag cccacaggga accgcctcag caagagtggc ctgaagggt 840  
gtgtctatgg acaggaggca gtgcgtctct ccgtggggcc catggcccgg gacgtggaga 900  
gcctggcact gtgcctgcga gccctgctgt gcgaggacat gttccgcttg gacccactg 960  
tgccctccctt gcccttcaga gaagaggtct acaccagctc tcagcccctg cgtgtggggt 1020  
actatgagac tgacaactat accatgccct ccccgccat gaggcgggcc gtgctggaga 1080  
ccaaacagag ccttgaggct gcggggcaca cgctgggtcc cttcttgcca agcaacatac 1140  
cccatgctct ggagaccctg tcaacagggt ggctcttcag tgatgggtgg cacaccttc 1200  
tacagaactt caaaggatgat ttcgtggacc cctgcctggg ggacctggtc tcaattctga 1260  
agcttcccca atggcttaaa ggactgctgg ccttcctggt gaagcctctg ctgccaaggc 1320  
tgtcagcttt cctcagcaac atgaagtctc gttcggcttg aaaactcttg gaactgcagc 1380  
acgagatcga ggtgtaccgc aaaaccgtga ttgccagtg gagggcgctg gacctggatg 1440  
tggtgctgac ccccatgctg gccctgctc ttgacttgaa tgcccaggc agggccacag 1500  
gggcccgcag ctacactatg ctgtacaact gcctggactt ccctgcaggg gtggtgcctg 1560  
tcaccacggt gactgctgag gacgagggcc agatggaaca ttacaggggc tactttgggg 1620  
atatctggga caagatgctg cagaagggca tgaagaagag tgtggggctg ccgtggccg 1680

```

tgcagtgtgt ggcttggccc tggcaagaag agtttgtgtct gcggttcatg cgggaggtgg 1740
agcgactgat gaccctgaa aagcagtcac cctgatggct ctggctccag aggacctgag 1800
actcacactc tctgcagccc agcctagtca gggcacagct gccctgctgc cacagcaagg 1860
aaatgtcctg catggggcag aggcctccgt gtcctctccc ccaaccccct gcaagaagcg 1920
ccgactccct gagtctggac ctccatccct gctctggtec cctctcttcg tcctgatccc 1980
tccaccccca tgtggcagcc catgggtatg acataggcca aggcccaact aacagtcaag 2040
aaacaaaaaa aaaaaaaaaa aaa 2063

```

```

<210> 8
<211> 579
<212> PRT
<213> homo sapiens

```

```

<400> 8

```

```

Met Val Gln Tyr Glu Leu Trp Ala Ala Leu Pro Gly Ala Ser Gly Val
1           5           10           15

```

```

Ala Leu Ala Cys Cys Phe Val Ala Ala Ala Val Ala Leu Arg Trp Ser
20           25           30

```

```

Gly Arg Arg Thr Ala Arg Gly Ala Val Val Arg Ala Arg Gln Lys Gln
35           40           45

```

```

Arg Ala Gly Leu Glu Asn Met Asp Arg Ala Ala Gln Arg Phe Arg Leu
50           55           60

```

```

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Pro
65           70           75           80

```

```

Gln Leu Val Gln Lys Leu His Ser Arg Glu Leu Ala Pro Glu Ala Val
85           90           95

```

```

Leu Phe Thr Tyr Val Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn
100          105          110

```

```

Cys Val Thr Ser Tyr Leu Ala Asp Cys Glu Thr Gln Leu Ser Gln Ala
115          120          125

```

```

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys
130          135          140

```

```

Phe Thr Tyr Lys Gly Gln Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu
145          150          155          160

```

```

Gly Val Pro Ala Glu Cys Asp Ser Val Val Val His Val Leu Lys Leu
165          170          175

```

```

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe
180          185          190

```



Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Val Asn Pro Trp  
195 200 205

Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240

Ser Ile Arg Phe Pro Ser Ser Phe Cys Gly Ile Cys Gly Leu Lys Pro  
245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly  
260 265 270

Gln Glu Ala Val Arg Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu  
275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg  
290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Thr  
305 310 315 320

Ser Ser Gln Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Val Leu Glu Thr Lys Gln Ser  
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Ser Asn Ile  
355 360 365

Pro His Ala Leu Glu Thr Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly  
370 375 380

Gly His Thr Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
385 390 395 400

Leu Gly Asp Leu Val Ser Ile Leu Lys Leu Pro Gln Trp Leu Lys Gly  
405 410 415

Leu Leu Ala Phe Leu Val Lys Pro Leu Leu Pro Arg Leu Ser Ala Phe  
420 425 430

Leu Ser Asn Met Lys Ser Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln  
435 440 445

His Glu Ile Glu Val Tyr Arg Lys Thr Val Ile Ala Gln Trp Arg Ala  
450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ala Pro Ala Leu Asp  
465 470 475 480

Leu Asn Ala Pro Gly Arg Ala Thr Gly Ala Val Ser Tyr Thr Met Leu  
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Arg Gly Tyr Phe Gly  
515 520 525

Asp Ile Trp Asp Lys Met Leu Gln Lys Gly Met Lys Lys Ser Val Gly  
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys  
565 570 575

Gln Ser Ser

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)


PCT

(10) International Publication Number  
**WO 2004/037371 A2**

- (51) International Patent Classification<sup>7</sup>: **B01D** (US). **WILSON, Sandy, J.** [US/US]; 10669 Carmel Mountain Road, San Diego, CA 92129 (US). **MAZUR, Curt** [US/US]; 943 Armada Terrace, San Diego, CA 92106 (US).
- (21) International Application Number: PCT/US2003/033354
- (22) International Filing Date: 21 October 2003 (21.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/420,065 21 October 2002 (21.10.2002) US
- (71) Applicant (for all designated States except US): **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BARBIER, Ann, Johanna** [BE/US]; 7421 Eads Avenue, La Jolla, CA 92037
- (74) Agents: **ELDERKIN, Dianne** et al.; Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE



(57) Abstract: The invention provides methods of assaying fatty acid amide hydrolase (FAAH) activity adaptable for high throughput screening. The methods provide for separating a labeled substrate from at least one labeled hydrolysis product, the separation facilitating the quantification. The invention also provides methods of identifying a compound to be tested as an inhibitor or an activator of FAAH activity through the addition of the compound to be tested to a reaction mixture and comparison of the enzyme activity in the presence and absence of the compounds to be tested. The methods are adaptable for use in detecting altered FAAH activity in patients, for example, those at risk for *in vitro* fertilization failure, or at risk for, or suffering from, addictions.

WO 2004/037371 A2



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(15) Information about Correction:

see PCT Gazette No. 34/2004 of 19 August 2004, Section II

**Published:**

— *without international search report and to be republished upon receipt of that report*

(48) Date of publication of this corrected version:

19 August 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*